title: Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma.
abstract: The mTOR inhibitor everolimus is currently approved for the treatment of renal cell carcinoma (RCC) and several Toll-like receptor 9 (TLR9) agonists, including immunomodulatory oligonucleotides (IMOs), have been tested for their therapeutic potential against advanced RCC. However, no clinical trials investigating the combination of mTOR inhibitors with TLR9 agonists in RCC patients have been performed to date. Our results may pave the way to translate this combinatorial approach to the clinical setting.
authors.affiliation: Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica; Università di Napoli "Federico II"; Naples, Italy.
authors.forename: Roberta
authors.initials: R
authors.lastname: Rosa
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Damiano
authors.forename: Luigi
authors.initials: L
authors.lastname: Formisano
authors.forename: Lucia
authors.initials: L
authors.lastname: Nappi
authors.forename: Roberta
authors.initials: R
authors.lastname: Marciano
authors.forename: Bianca Maria
authors.initials: BM
authors.lastname: Veneziani
authors.forename: Sabino
authors.initials: S
authors.lastname: De Placido
authors.forename: Roberto
authors.initials: R
authors.lastname: Bianco
keywords: TLR9; everolimus; mTOR; microenvironment; renal cell carcinoma